摘要
目的 :对比NP和MVP两组方案治疗晚期非小细胞肺癌的疗效和毒性。方法 :通过NP和MVP两个联合化学治疗方案每 2 1～ 2 8天周期全身给药的方法共收治晚期非小细胞肺癌 2 46例 ,其中腺癌 15 9例 ,鳞癌 5 5例 ,其他 32例。初治 177例 ,复治 6 9例。结果 :NP组和MVP组有效率分别为 35 7% (35 / 98)和 34 5 % (5 1/ 148) ,两组无显著性差异 (P >0 0 5 )。中位缓解期NP组为 5个月 ,MVP组为 4个月 ;中位生存期NP组为 11个月 ,MVP组为 8个月 ,均无显著性差异。毒副作用主要是骨髓抑制。Ⅲ～Ⅳ度白细胞下降率NP组为 5 0 0 % ,MVP组为 38 5 % ,两组间有显著差异 (P <0 0 5 ) ,Ⅲ～Ⅳ度血小板下降率NP组为 4 1% ,MVP组为 7 4% (P >0 0 5 )。Ⅲ～Ⅳ度消化道反应两组发生率分别为 15 3%和 18 2 %且以Ⅲ度为主。结论 :NP和MVP两方案治疗晚期非小细胞肺癌有效率较高且相似 ,中位生存期虽无明显差异但NP方案较长。白细胞下降的副反应虽有差异性但均可耐受。因此 ,从不同的需要和考虑出发 ,两者均可作为治疗晚期非小细胞肺癌的首选方案。
Objective: To compare the efficacy and toxicity in the treatment of non-small-cell lung cancer (NSCLC) with NP and MVP regimen Methods: Through every 21 to 28 days cycle, systemic administration of NP and MVP combination chemotherapeutic regimen, a total of 246 cases of advanced stage non-small-cell lung cancer were enrolled Among them, 159 cases were adenocarcinoma, 55 squamous cell carcinoma and 32 others Chemotherapy-naive patients account for 177 cases and 69 recurrent diseases Results: The response rate were 35 7%(35/98) for NP regimen and 34 5%(51/148) for MVP regimen respectively There was no statistical significant difference ( P >0 05) between them Median time to progression were 5 months for NP and 4 months for MVP Median survival time were 11 months for NP and 8 months for MVP There was no significant difference ( P >0 05) for both of them between two groups The major toxicity was bone marrow suppression Grade Ⅲ～Ⅳleukopenia occurred in 50%of the NP group and 38 5%of the MVP group There was a significant difference ( P < 0 05) between two groups Grade Ⅲ～Ⅳthrombocytopenia was 4 1%in NP group and 7 4%in MVP group ( P >0 05) In grade Ⅲ～Ⅳ, nausea and vomiting were observed in 15 3%with NP and 18 2%with MVP ( P >0 05) and mainly occurred with grade Ⅲtoxicity in both groups Conclusion: Higher but similar response rates were seen in patients with NSCLC treated with NP and MVP regimens The median survival, although not significant was in favor of NP regimen Significant leukopenia occurred but was all tolerated well
出处
《中国肿瘤临床》
CAS
CSCD
北大核心
1999年第12期914-917,共4页
Chinese Journal of Clinical Oncology
关键词
非小细胞肺癌
对比
药物疗法治疗
Non-small-cell lung cancer/chemotherapy Vindesine Cisplatin Mitomycin Navelbine Comparative study
